FSC-2023
15.3.2023 16:48:34 CET | Business Wire | Press release
The second edition of the Financial Sector Conference (FSC 2023) opened today in Riyadh, welcoming over 3000 participants from around the world to discuss the way ahead for the global financial community under the conference theme of “Promising Financial Prospects.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005659/en/
Saudi Minister of Finance HE Mohammed Al-Jadaan addresses delegates at opening of Financial Sector Conference in Riyadh, Saudi Arabia (Photo: AETOSWire)
Welcoming delegates to the conference Saudi Minister of Finance HE Mohammed Al-Jadaan said: “I am confident that this conference will be an opportunity to build on experiences and share ideas to address a global economy which is full of challenges and opportunities—helping to make the global financial sector stronger, more influential and resilient.”
The conference opened with a powerful panel discussion examining the strategic options for the financial sector in light of challenging global economic circumstances. Credit Suisse Group AG Chairman Axel Lehmann told the audience: “What is clear is that over the past 10 to 15 years the massive geopolitical shifts we have seen are generating new economic opportunities in places like the Middle East which is becoming a vibrant new global centre along with places such as China and India.”
Commenting on opportunities emerging in Saudi Arabia, State Street Chairman and CEO Ronald O’Hanley added: “For investors it is clearly a very attractive time to be here with a strong economy and a Government that is committed to transition and powered by a well-educated workforce. There are clear investment opportunities in energy and renewables, in tourism and to benefit from the rise in the consumer economy.”
HE Eng. Khalid Al Falih, Saudi Arabia’s Minister of Investment, said: “We are now halfway to implementing Vision 2030 that will triple the scale of the economy and we are ahead of schedule but we know we cannot be complacent. One of the biggest shifts emerging is that in the past we were seen as a source of capital but that is being reversed today and we are urging the financial community to be aware of the opportunities and we aim to attract more capital and international partners.”
Alexandre Fleury, Co-Head of Market Activities, Societe Generale, told the conference: “Vision 2030 is extraordinary and an amazing achievement. But the world has not noticed enough what is happening in Saudi Arabia but soon investors will have no choice but to invest here. Global investors have to be a part of Vision 2030.”
Looking at the global economic situation, Seth Carpenter, Global Chief Economist, Morgan Stanley, “As Morgan Stanley, we are pretty optimistic about Asia, specifically China, Japan, India and Saudi Arabia. The weakest growth is in Europe and the US although economic performance is high. The quandary for central banks is how much you raise interest rates in order to bring inflation down; and judging exactly how much you need to slow things down without causing a recession.”
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005659/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
